Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Nurix Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Nurix Therapeutics, Inc.’s stock price such as:

• Nurix Therapeutics, Inc.’s current stock price and volume
• Why Nurix Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for NRIX from analysts
• NRIX’s stock price momentum as measured by its relative strength

About Nurix Therapeutics, Inc. (NRIX)

Before we jump into Nurix Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Want to learn more about Nurix Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Nurix Therapeutics, Inc..

Nurix Therapeutics, Inc.’s Stock Price as of Market Close

As of May 20, 2026, 4:00 PM, CST, Nurix Therapeutics, Inc.’s stock price was $16.420.

Nurix Therapeutics, Inc. is up 7.74% from its previous closing price of $15.240.

During the last market session, Nurix Therapeutics, Inc.’s stock traded between $15.320 and $16.500. Currently, there are approximately 110.07 million shares outstanding for Nurix Therapeutics, Inc..

Nurix Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Nurix Therapeutics, Inc. Stock Price History

Nurix Therapeutics, Inc.’s (NRIX) price is currently down 1.68% so far this month.

During the month of May, Nurix Therapeutics, Inc.’s stock price has reached a high of $17.390 and a low of $15.070.

Over the last year, Nurix Therapeutics, Inc. has hit prices as high as $22.500 and as low as $8.195. Year to date, Nurix Therapeutics, Inc.’s stock is down 13.44%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Nurix Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 20, 2026, there were 3 analysts who downgraded Nurix Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Nurix Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Nurix Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Nurix Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Nurix Therapeutics, Inc. (NRIX) by visiting AAII Stock Evaluator.

Relative Price Strength of Nurix Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 20, 2026, Nurix Therapeutics, Inc. has a weighted four-quarter relative price strength of 5.72%, which translates to a Momentum Score of 75 and is considered to be Strong.

Want to learn more about how Nurix Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Nurix Therapeutics, Inc. Stock Price: Bottom Line

As of May 20, 2026, Nurix Therapeutics, Inc.’s stock price is $16.420, which is up 7.74% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Nurix Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.